Hepatitis A Vaccine (Inactivated Viral)
AVAXIM®  
Supplier: Sanofi Pasteur Limited
AVAXIM® Pediatric  
Supplier: Sanofi Pasteur Limited
(Adult presentation: 160 antigen units/0.5 mL; Pediatric presentation: 80 antigen units/0.5 mL)

INDICATIONS:
• See Hepatitis A Vaccine Indications

DOSES AND SCHEDULE:  
Routine Aboriginal infant series:  
2 doses given as 0.5 mL of AVAXIM® Pediatric (80 antigen units) IM at 6 and 18 months of age.

Other eligible individuals:

6 months-15 years of age (inclusive):  
2 doses given as 0.5 mL of AVAXIM® Pediatric (80 antigen units) IM, separated by 6 months.

16 years of age and older:  
2 doses given as 0.5 mL of AVAXIM® (160 antigen units) IM, separated by 6 months.

ADMINISTRATION:
No additional requirements.

BOOSTER DOSES:
No booster doses are recommended at this time.

SEROLOGICAL TESTING:
Serological testing may be indicated prior to immunization for select special populations, see Part 2 – Immunization of Special Populations. Post-vaccination serological testing is not indicated following a hepatitis A vaccine series.

CONTRAINDICATIONS:
1. History of anaphylactic reaction to a previous dose of any hepatitis A vaccine, or to any component of AVAXIM® or AVAXIM® Pediatric.

A Hepatitis A vaccines may be used interchangeably using the age-appropriate dose for the product being given.
B AVAXIM® Pediatric is approved for use in children 1-15 years of age (inclusive). However, NACI indicates that hepatitis A vaccine may be provided, beginning at 6 months of age, to infants who are at increased risk of infection or severe hepatitis A.
C Aboriginal children remain eligible for hepatitis A vaccine up to and including 18 years of age using the age-appropriate dosing and schedule.
D For HIV positive individuals, provide 3 doses of vaccine at 0, 1 and 6 months.
Hepatitis A Vaccine (Inactivated Viral)
AVAXIM®  Supplier: Sanofi Pasteur Limited
AVAXIM® Pediatric  Supplier: Sanofi Pasteur Limited

PRODUCT COMPONENTS:
Potential allergens: neomycin, polysorbate 80.
Other components: formaldehyde, aluminum hydroxide, 2-phenoxyethanol, Medium 199.

PRECAUTIONS:
Not applicable.

SPECIAL CONSIDERATIONS:
For more information related to pre-exposure prophylaxis against hepatitis A related to travel, refer clients to their local travel clinic.

ADVERSE EVENTS:
Local: soreness, redness.
Systemic: headache, fatigue, fever, malaise, nausea, vomiting, diarrhea.